Offer - Urjas Oil for just ₹ 1 X
Thyropil 25 Mcg Tablet is a commercial drug that is prescribed in the form of Tablet. It is typically used for the treatment of Hypothyroidism. Secondary and off-label uses of Thyropil 25 Mcg Tablet have also been mentioned below.
Medical history of the patient along with age and gender determines the dosage of Thyropil 25 Mcg Tablet. The condition it has been prescribed for, and the route of administration also determine the right dosage. Refer to the dosage section for a detailed discussion.
Apart from the aforementioned side effects, Thyropil 25 Mcg Tablet can also lead to other problems, which have been listed below. Such side effects of Thyropil 25 Mcg Tablet normally do not last long and go away once the treatment is completed. If, however, they worsen or do not go away, please speak with your physician.
Furthermore, you should know that effect of Thyropil 25 Mcg Tablet is Safe for pregnant women and Mild for women who are breastfeeding. Warnings related to Thyropil 25 Mcg Tablet's effects on the liver, heart and kidney, if any, have been listed below.
Thyropil 25 Mcg Tablet can cause adverse effects in certain medical conditions. It is strongly recommended to avoid Thyropil 25 Mcg Tablet in conditions like Heart Disease, Hypopituitarism. Other conditions have been mentioned below in the Thyropil 25 Mcg Tablet contraindications section.
Besides this, Thyropil 25 Mcg Tablet may also have severe interaction with some medicines. A complete list of these interactions is given below.
Along with the above-mentioned precautions, remember that taking Thyropil 25 Mcg Tablet is considered safe while driving, and is addictive.
Thyropil 25 Mcg Tablet is used to treat the following -
Main Benefits
Other Benefits
This is the usual dosage recommended in most common treatment cases. Please remember that every patient and their case is different, so the dosage can be different based on the disease, route of administration, patient's age and medical history.
Find the right dosage based on disease and age
Age Group | Dosage |
Adult |
|
Geriatric |
|
13 - 18 years (Adolescent) |
|
2 - 12 years (Child) |
|
Infant (1 month to 2 years) |
|
Neonates (0 to 1 month) |
|
Is the use of Thyropil 25 Mcg Tablet safe for pregnant women?
Thyropil is safe to take during pregnancy.
Is the use of Thyropil 25 Mcg Tablet safe during breastfeeding?
Thyropil may have very limited harmful effects for breastfeeding women.
What is the effect of Thyropil 25 Mcg Tablet on the Kidneys?
Thyropil does not damage the kidneys.
What is the effect of Thyropil 25 Mcg Tablet on the Liver?
Thyropil is not harmful for the liver.
What is the effect of Thyropil 25 Mcg Tablet on the Heart?
Using Thyropil does not have any harmful effects on the heart.
If you are suffering from any of the following diseases, you should not take Thyropil 25 Mcg Tablet unless your doctor advises you to do so -
Is this Thyropil 25 Mcg Tablet habit forming or addictive?
Forming a habit of Thyropil 25 Mcg Tablet has not been reported.
Is it safe to drive or operate heavy machinery when consuming?
Yes, it is safe to do these activities or work after taking Thyropil 25 Mcg Tablet as it does not make you drowsy.
Is it safe?
Yes, Thyropil 25 Mcg Tablet is safe but you must consult your doctor before taking it.
Is it able to treat mental disorders?
There is no benefit of taking Thyropil 25 Mcg Tablet for mental disorders.
Interaction between Food and Thyropil 25 Mcg Tablet
Taking Thyropil 25 Mcg Tablet with food does not harm your health.
Interaction between Alcohol and Thyropil 25 Mcg Tablet
No research has been done on this till date. Therefore, it is not known what the effect of taking Thyropil 25 Mcg Tablet with alcohol will be.
This medicine data has been created by -
B.Pharma, Pharmacy
5 Years of Experience
References
US Food and Drug Administration (FDA) [Internet]. Maryland. USA; Package leaflet information for the user; Levoxyl (levothyroxine sodium)
April Hazard Vallerand, Cynthia A. Sanoski. [link]. Sixteenth Edition. Philadelphia, China: F. A. Davis Company; 2019: Page No 769-770